Gene therapy injection shows promise for blinding eye disease
NCT ID NCT05903794
First seen Apr 24, 2026 · Last updated Apr 26, 2026 · Updated 1 time
Summary
This early-stage study tested a new gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration, a leading cause of vision loss. The treatment aims to block abnormal blood vessel growth and leakage in the eye. The main goal was to check if the therapy is safe and tolerable before testing if it can improve vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Sierra Eye Associates
Reno, Nevada, 89502, United States
Conditions
Explore the condition pages connected to this study.